lunes, 10 de junio de 2024

Cost-effectiveness of brentuximab vedotin compared with conventional chemotherapy for relapsed or refractory classic Hodgkin lymphoma in China

https://healtheconomicsreview.biomedcentral.com/

No hay comentarios: